Graft-versus-host disease: the transplant fighting back, and why a little of it is the point
Last updated September 3, 2026.
Graft-versus-host disease, GvHD, is what happens when the immune system you received in a stem cell or bone marrow transplant recognizes your body as foreign and attacks it: the skin with rashes, the gut with diarrhea, the liver with rising enzymes, the mouth, eyes, and lungs in the chronic form. It is the shadow side of the transplant's great gift, because the same donor immunity that attacks you is the immunity that hunts the remaining cancer, and the entire art of the transplant team is holding that balance. The acute form strikes in the first months; the chronic form creeps in later and can smolder for years. Treatment is immune suppression, steroids first, with newer drugs for the steroid-resistant, titrated constantly: enough to protect your organs, not so much that the cancer protection or the infection defenses are lost entirely. Most acute cases respond; chronic GvHD often improves over years, and many people taper off treatment entirely. The practical realities are real: infection vigilance while suppressed, sun protection for the skin, dental and eye care, and a long relationship with the transplant clinic. The framing worth keeping: some graft-versus-host reaction is the signature of a graft that is working, and the goal is a truce, not a surrender.
What does it look like?
Acute, in the first months: a rash that can be mild or angry, watery diarrhea sometimes in large volumes, and the liver's enzymes rising on blood tests. Chronic, later: dry eyes and mouth, skin that tightens or thickens, stiff joints, breathlessness from lung involvement, fatigue, and weight loss. The chronic form often starts subtly, and the transplant clinic's surveillance exists precisely to catch it at the subtle stage.
Why does it happen?
The donated immune system sees your tissues as foreign and mounts an attack, the mirror image of rejection in an organ transplant. The risk rises with how different the donor's tissue type is, the donor and recipient ages, and the transplant's specifics, but it strikes even perfectly matched transplants, because minor differences remain. It is not a mistake, not a failed transplant, and not something anyone could have prevented: it is a known, managed feature of the treatment that saved your life.
How is it treated?
- Steroids are the first line, titrated to the balance. They quiet the attacking immune system, and the dose is a constant negotiation: enough to protect your skin, gut, and liver, not so much that the graft's cancer-hunting work and your infection defenses are lost.
- Newer drugs handle the steroid-resistant cases. When steroids are not enough, or their side effects pile up, a growing list of targeted immune drugs takes over, and the transplant centers know the sequencing well.
- Infection vigilance is the daily discipline. Immune suppression lowers the defenses, so fevers are reported immediately, food and contact precautions are followed, and the prophylactic antibiotics and antivirals are taken exactly.
- The chronic form gets long-term, whole-body care. Eyes, mouth, skin, joints, and lungs each get their own therapies, from drops to physiotherapy, and the slow improvement over years, often to the point of tapering off treatment, is the expected arc for many.
When does it need urgent review?
Fever during immune suppression is a same-day call, every time. A fast-spreading rash, heavy diarrhea, yellowing eyes, new breathlessness, or inability to keep fluids down each deserve same-day contact with the transplant team. Pymander's escalation routing is built and tested specifically for this class of decision; see the safety architecture working paper.
What a Pymander AI doctor consult looks like
Illustrative example, not a real member's messages.
Common questions
The nurse said a little of this is a good sign. How can that be true?
Because the same immune system is doing both jobs. The donor immunity you received sees two things as foreign: your leukemia, and, because minor differences remain even in a matched transplant, some of your normal tissues. The attack on your skin and gut is the same attack that patrols for the cancer, and the data are consistent: people with mild, controlled graft-versus-host disease have lower relapse rates than people with none. So a little is indeed the signature of a graft that is awake and hunting. The goal is never zero reaction and never a severe one: it is the truce in the middle, and the steroids are the negotiating tool, titrated constantly to keep the graft's aim on the cancer and off your organs.
Does this mean the transplant is failing?
No, and the headline evidence is already in your message: the leukemia is gone, and the graft is the reason. Graft-versus-host disease is not a failed transplant; it is a known, managed feature of a working one, common enough that the team watches for it from day one and treats it as routine work. The transplants that fail look different: the graft not taking hold, or the leukemia returning, and neither is your story. What you have is the complication of success, with the volume turned too high, and the steroids are the volume knob. Most acute cases respond over days to weeks.
What is actually happening in my body right now?
Your new immune system, which is the donor's, is reading some of your tissues as foreign and attacking them, the mirror image of organ rejection. The skin gets the rash, the gut lining gets the diarrhea, and the liver shows it on the blood tests, because those are the tissues the attacking cells reach first. The steroids blunt that attack, and the team adjusts the dose against your symptoms and your blood work, sometimes daily, because the dose is a balance: enough to protect your organs, not so much that the graft's cancer-hunting and your infection defenses are lost. When steroids are not enough, a growing list of targeted immune drugs takes over, and the transplant centers know the sequencing well.
The steroids are making me ravenous, sleepless, and strange. Is that permanent?
No, and naming it helps: high-dose steroids are famous for the hunger, the 3 a.m. wakefulness, the mood swings, the puffiness, and the strange energy, and every patient on them wonders whether this is who they are now. It is not: these are drug effects, they track the dose, and they retreat as the dose is tapered, which is the plan the moment your symptoms allow. Report them rather than endure them, because some are worth managing in their own right, and the team needs to know the total picture to titrate well. The strange weeks belong to the medicine, not to you, and they have an end date the treatment is working toward.
What rules matter while I am on this much immune suppression?
One absolute and a handful of habits. The absolute: a fever is a same-day call to the transplant team, every time, day or night, because your defenses are lowered and infections move fast. The habits: the prophylactic antibiotics and antivirals taken exactly, because they are the standing guard; the food precautions your team gave you followed while suppressed; sun protection, because GvHD skin is sun-sensitive; and the symptom diary, the rash, the diarrhea, the mouth, kept honestly, because its direction is what the dose adjustments are reading. None of it is forever: it is the discipline of the suppressed months, and it relaxes as the drugs taper.
Is this going to become the chronic version? What is my future here?
Some acute cases do evolve into the chronic form, and the honest answer is that time and your response tell, with the clinic's surveillance built to catch the transition at its subtle stage. If it comes, the chronic form is a different, slower creature: dry eyes and mouth, skin tightening, stiff joints, sometimes lung involvement, managed with its own long-term toolkit, and the arc for many people is improvement over years, often to the point of tapering off treatment entirely. The statistics worth keeping close: most acute cases respond, the leukemia being gone is the headline, and the team managing your GvHD is the same team that got you this far. The future here is managed, watched, and, in the large picture, pointing the right way.